1. In Vivo
  2. >>Innovation

Changing The Game With The Echo Exam: Philips Ultrasound

On The ESC Agenda: The Evolving Ultrasound Market And Integrating Israeli Company DiA

 
• By Ashley Yeo

On the eve of the 2023 European Society of Cardiology meeting, senior Philips ultrasound directors spoke to In Vivo about the company’s strategies to maintain cardiac market leadership, building on internal and externally acquired strengths and evolving attitudes to AI in product development and use.

LinkedIn Philips at ESC
Philips' Dave Handler at ESC 2023, Amsterdam • Source: Philips ESC LinkedIn video

Cardiovascular disease applications represent upwards of €1bn ($1.1bn) of the ultrasound market. Royal Philips is number one globally in this segment, but Jeff Cohen, the company’s global general manager of ultrasound, insists that there is always work to do to ensure market supremacy is maintained.

Speaking to In Vivo during the company’s final preparations for the 2023 European Society of Cardiology (ESC) conference in Amsterdam,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Innovation

Finding The Fire: AltruBio’s Novel Approach To Autoimmune Disease

 
• By David Wild

CEO Judy Chou brings big pharma experience to tackle chronic inflammation with the company's first-in-class PSGL-1 targeting therapy.

Late-Stage GLP-1 Drug Trials Outside The Cardiometabolic Space

 
• By David Wild

A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By Ashley Yeo

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By Ashley Yeo

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

More from In Vivo

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By Ashley Yeo

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By Ashley Yeo

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By David Wild

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.